Welcome to #NephMadness 2026 Our beautiful baby has grown into a moody, hormonal teen.  That’s right, it’s year 14 of NephMadness!  Whether this is your first time or you are a seasoned veteran, we have all the inf…

Happy #NephMadness Month!

The 8 regions of #NephMadness 2026 have been revealed on the #AJKDBlog.

If you're a #NephMadnessNewbie, we explain everything here:
bit.ly/NephMadness2...

Looking forward to the fun and learning with all of you!

A fascinating match in the #nephmadness 2026 trolls of transplantation region🏀.
I'm backing team BKV. A silent killer with no specific treatment and devastating graft outcomes.
Can virus-specific T-cell (VST) finally slay the troll?
Read more: ajkdblog.org/2026/03/01/n...

It’s March once again … #Nephmadness has begun #Nephpearls #NephSky

👉🏼 ajkdblog.org
👉🏼 If you don’t know what it’s about, then it’s time to checkout this 📺 m.youtube.com/watch?v=tZUR...

Diagram titled, 'Figure 1. Pathophysiology of IgA Nephropathy,' shows 'Four-hit hypothesis' of primary IgA nephropathy (IgAN). Steps include production of IgA1 immunoglobulins, entry into circulation, formation of immune complexes & deposition in glomerular mesangium.

IgA nephropathy is the most common cause of immune-mediated glomerular disease worldwide.

📌 This Review summarizes the pathophysiology, epidemiology, clinical presentation, diagnosis, treatment, and prognosis of primary IgA nephropathy in adults.

ja.ma/4jWE9ag

Potassium sparing diuretics are widely used in the management of hypertension, heart failure, and oedema.

What should you know when prescribing these drugs? #MedEd
www.bmj.com/content/392/...

Interesting review about membranous nephropathy.
It presents five interesting clinical cases highlighting the utility of antigen identification in guiding the management of membranous nephropathy.
@ajkd.bsky.social
DOI: 10.1053/j.ajkd.2025.08.013

Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD) ca. 2026 from @kdigo.org
#Nephpearls #NephSky

👉 kdigo.org/guidelines/a...

Prophylactic 2-week glecaprevir/pibrentasvir in hepatitis C positive-to-negative kidney transplantation

doi.org/10.1093/ndt/...

IgA Nephropathy #IgAN: An Overview of the Clinical Trials ca. 2025 from @kidneymed.bsky.social @alexgr23.bsky.social @saynanorouzi.bsky.social
#Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/41050133/

📣 𝗡𝗘𝗪 𝗧𝗢𝗢𝗟𝗞𝗜𝗧 𝗥𝗘𝗦𝗢𝗨𝗥𝗖𝗘: Get at-a-glance guidance on #ADPKD with our latest infographic, now part of the ISN Rare Kidney Diseases Toolkit! 🔗 http://lite.spr.ly/6...